Table D24. Morbidity outcomes 3

| Author, YearTrial Name | Morbidity Outcome 3 | Description of Timing of Measurement of Outcome  | Data source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Bogner et al., 20084NA | Diastolic BP, mean (SD), mm Hg - compared at 6 weeks | measured at baseline and at 6 weeks | automated BP monitor | G1: 32G2: 32 | G1: 75.8 (10.7)G2: 85.0 (11.9)95% CI, p: .002 |
| Choudhry et al., 201113MI FREEE | First fatal or nonfatal vascular event |  NA | health claims data | G1: 2845G2: 3010 | G1: 329 patients; 11.0 per 100 person-yearsG2: 405 patients; 12.8 per 100 person-yearsAdjusted hazard ratio: 0.86, 95% CI, 0.74-0.99p: 0.03 |
| Janson et al., 200320NA | Perceived control of asthma at week 7; between group difference in change from baseline to final visit at week 7 (95% CI)  | timeframe of measure not reported; measured at each study visit | questionnaire | G1: 33G2: 32 | G1: 42 (5)G2: 42 (5)Between group difference: 2.6 (0.1 to 5), p= 0.04 |
| Janson et al., 200921NA | Mean change Eosinophil cationic protein (ECP) (nanograms/mL);Eosinophils > 0% (> 1/500 cells), During intervention(T0-T1), following intervention (T1-T2), and for entire study duration (T0-T2) | collected once at the end of each time period; During intervention(T0-T1), following intervention (T1-T2), and for entire study duration (T0-T2) | sputum sample | G1: 45G2: 39 | **T0-T1**G1: 0.88G2: 1.05p: 0.55**T1-T2**G1: 0.88 G2: 1.1195% CI, p: .44**T0-T2**G1: 0.77G2: 1.17p: 0.18Odds Ratios of >0% ECP**T0-T1**:G1: 0.5G2: 1.0p: 0.4**T1-T2**:G1: 3.1G2: 0.6p: 0.09**T0-T2:**G1: 1.7G2: 0.6p: 0.29 |
| Katon et al., 200128NALudman et al., 200329NAVan Korff et al., 200330NA | Functional impairment (Von Korff et al.) | BL, 3, 6, 9, 12 months  | Self-report, SF-36 Social functioning Scale( using imputed data and adjusting for age, sex, chronic disease score, neuroticism, and baseline SCL)  | **BL**G1: 194G2: 192**3 mos**G1: 186G2: 186**6 mos**G1: 181G2: 170**9 mos**G1: 175G2: 164**12 mos**G1: 174G2: 153 | **3 mos** mean (SD)G1: 81.4 (20.5)G2: 81.1 (21.1) 95% CI, NR p: NR**6 mos** mean (SD)G1: 83.3 (20.2)G2: 83.0 (20.9)95% CI, NR p: NR**9 mos** mean (SD)G1: 84.7 (19.7)G2: 81.4 (22.4) 95% CI, NR p: NR**12 mos** mean (SD)G1: 86.9 (17.8)G2: 81.7 (20.4)95% CI, NR p: NREffects:InterventionEstimate: 0.27 (1.42)T-statistic: 0.19p: 0.85TimeEstimate: 0.66 (0.48)T-statistic: 1.38p: 0.17Intervention x timeEstimate: 1.31 (0.66)T-statistic: 1.98p: 0.047 |
| Katon et al., 199625NA | 50% or more improvement on IDS | 4-month follow up | IDS | G1: 77G2: 76 | Major Depression Group (% showing >50% improvement)G1: 74.1%G2: 42.3%p:0.02No significant differences between G1 and G2 in the minor depression groupG1: 51.3%G2: 52.8%p: 0.90  |
| Lin et al., 200632NA | Adjusted mean BMI difference (baseline minus endpoint) | NA | NR | **BL**G1: 164G2: 165**EP**G1: 164G2: 165 | **BL** (kg/m^2) = NA95% CI, NAp: NA**EP** (kg/m^2) = 0.7095% CI, 0.17 to 1.24p: <0.01 with adjustment |
| Pearce et al., 200839Cardiovascular Risk Education and Social Support (CaRESS) Trial | Mean LDL cholesterol level | 6 times over a 12-month period | Phlebotomy during study practice site visits | BLG1 + G2: 24 G3: 16MidpointG1 + G2: 18G3: 11EndpointG1 + G2: 18G3: 11 | **BL**G1 + G2: 137.0 G3: 137.395% CI, NRp (G1 + G2 vs. G3): 0.9471 (unadjusted), NA (adjusted)**Midpoint**G1 + G2: 139.4G3: 130.595% CI, NRp (G1 + G2 vs. G3): 0.6716 (unadjusted), NA (adjusted)**EP**G1 + G2: 135.4G3: 110.695% CI, NRp (G1 + G2 vs. G3): 0.3238 (unadjusted), NA (adjusted) |
| Schaffer et al., 200447NA | PQAQ(higher=better): mean | baseline, 3, 6 months; timeframe: specific to time of measurement | questionnaire | G1: 11G2: 10G3: 12 G4: 13 | G1: Pre: 43.72 (5.14)3 mo: 49.90 (4.6)6 mo: 43.33 (14.43)G2: Pre: 42.70 (6.696)3 mo: 44.0 (4.97)6 mo: 44.20 (6.16)G3 :Pre: 44.50 (4.62)3 mo: 45.75 (6.27)6 mo: 43.33 (14.44)G4:Pre: 44.61 (6.47)3 mo: 44.67 (6.82)6 mo: 45.27 (5.57)Pre-3: G4 vs. G2 p = .8 G4 vs. G1 p = .6 G4 vs. G3 p = .3 Pre-6G4 vs. G3 p = .2G4 vs. G2 p = .4G4 vs. G1 p = .8 |
| Schneider et al., 200849NA | Occurrence of angina | 6 and 12 months for the past 6 months | Medical chart review | G1: 47G2: 38 | G1: NRG2: NR95% CI, NRp: NRNumbers not reported, but results were not significant |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT | Change in Asthma control;  | measured baseline and at FU year 1; measured for the preceding 4 weeks and reported as change in ATAQ score | Asthma Therapy Assessment Questionnaire (ATAQ); 4-item scale. | G1: 182G2: 180G3: 189 | Change in ATAQ scoreG1: -.80G2: -.54G3: -.46ATAQ =0 (no asthma control problems)G1:G3 OR: 1.995% CI, 1.3-2.9p-0.002G2:G3 OR: 1.695% CI, 1.1-2.4p=0.0239 |